Company intelligence / Profile preview

AnnJi Biotech

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

AJ201 demonstrated positive Phase 1/2a results in SBMA patients, showing clinically meaningful improvements in physical and muscle function, with a 17.6-meter gain in 6-Minute Walk Test and 0.8-point increase in SBMA Functional Rating Scale compared to placebo.[10] Notably, nuclear mutant androgen receptor levels were reduced by more than 50% in 53% of AJ201-treated patients versus 17% of placebo, with RNA sequencing confirming Nrf2 pathway activation.[10]

Therapeutic areas: OtherPulmonologyNeurologyDermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Avenue Therapeutics (AJ201 licensing agreement; $253 million deal announced October 2023)[4]

Beyond the preview

Go deeper on AnnJi Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AnnJi Biotech.

Explore the full profile